From October 8 to 10, the CPHI Worldwide 2024 was held at Fiera Milano in Italy. With the theme of "The Partner of Choice", Henlius showcased 6 launched products, its robust biologic pipeline and integrated global biopharmaceutical platform. Henlius drew a large crowd at the booth, and concluded the conference with over 250 meetings.
As the largest professional exhibition in the global pharmaceutical industry, CPHI Worldwide has successfully held 35 editions to date. During the exhibition, the company held an experience sharing seminar themed "The Partner of Choice." At the seminar, Sandy Yan, Deputy GM of Regulatory Affairs at Henlius, delivered a keynote speech on the experiences of accelerating the internationalization of China's biosimilars from a regulatory perspective. Following this, together with Sandy, the company's President Wei Huang, Senior Vice President and Chief Business Development Officer Ping Cao, and Senior Vice President and Chief Technology Officer Simon Hsu participated in a panel discussion titled "Innovation Spirit and Partnership Philosophy at Henlius", which received enthusiastic responses and saw active interactions with several partners in attendance. This sharing seminar helped Henlius establish connections with many potential partners and clients, facilitating in-depth discussions on future collaboration opportunities.
Ping Cao, Senior Vice President and Chief Business Development Officer at Henlius, stated, "CPHI Worldwide brings together leading companies and professionals from the global pharmaceutical industry. We can not only delve into cutting-edge industry technologies but also engage in extensive exchanges with industry experts and peers, sharing success stories and practical outcomes. More importantly, it provides Henlius with an excellent opportunity to expand global cooperation network and identify more potential partners. Through deepening international collaboration, we are confident in continuing to advance the company's innovative initiatives and striving to provide high-quality and affordable biologics for patients worldwide."
During the exhibition, Henlius showcased 6 launched products at Booth #14A20, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in all China, Europe and the U.S., and its innovative product HANSIZHUANG (serplulimab), the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer.
Standing as the “pioneer in going global” for China-developed mAb biosimilar, Henliu has got its core oncology product HANQUYOU approved in 49 countries and regions around the world, making it the China-developed mAb biosimilar with the most marketing approvals. Until now, it has benefited more than 210,000 patients. The innovative product HANSIZHUANG has been approved in China for the treatment of microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer, extensive-stage small cell lung cancer, and esophageal squamous cell carcinoma. It has also been approved in Southeast Asian countries such as Indonesia, Thailand, and Cambodia, benefiting over 80,000 patients in total. Recently, Henlius received positive opinion from EMA CHMP for HANSIZHUANG as first-line treatment for extensive-stage small cell lung cancer, which is expected to further benefit more patients globally.
Leveraging the extensive commercialization experience of its business partners, Henlius is continually accelerating the expansion of its products in major markets as well as emerging markets. In 2024, Henlius expanded its collaboration with Sermonix in all of Asia to jointly advance the clinical development of the investigational novel targeted endocrine therapy HLX78 (lasofoxifene). Furthermore, Henlius reached cooperation with Convalife to further promote the commercialization of neratinib (trade name: HANNAIJIA). Recently, the first prescriptions for HANNAIJIA have been launched nationwide, marking its entry into clinical application and accelerating its commercialization process. Meanwhile, the company joined hands with international partners such as Accord, Eurofarma, KGbio and Organon to accelerate overseas registratoin and commercialization of its products, collectively advancing the innovation and globalization of China's biopharmaceutical industry.
Looking ahead, Henlius will remain focused on clinical needs, with a strong emphasis on oncology, autoimmune diseases, and other key areas. The company will continue to drive product innovation, expand its market presence, and deepen international cooperation to strengthen its global integrated platform of R&D, production, and commercialization. These efforts will further advance the internationalization of China’s biopharmaceutical innovations, delivering benefits to more patients worldwide.